MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines ; volume:11 ; number:1 ; day:30 ; month:5 ; year:2011 ; pages:1-11 ; date:12.2011
BMC cancer ; 11, Heft 1 (30.5.2011), 1-11, 12.2011
- Creator
-
Ohnstad, Hege O.
- Contributor
-
Paulsen, Erik B.
Noordhuis, Paul
Berg, Marianne
Lothe, Ragnhild A.
Vassilev, Lyubomir T.
Myklebost, Ola
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-11-211
- URN
-
urn:nbn:de:1111-2016030363100
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ohnstad, Hege O.
- Paulsen, Erik B.
- Noordhuis, Paul
- Berg, Marianne
- Lothe, Ragnhild A.
- Vassilev, Lyubomir T.
- Myklebost, Ola
- SpringerLink (Online service)
Other Objects (12)
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
Targeting MDM2, the antagonist of the tumor suppressor p53
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
The MDM2 gene family
Acid affairs in anti-tumour immunity
Antagonist
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
Targeting MDM2, the antagonist of the tumor suppressor p53
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
The MDM2 gene family
Acid affairs in anti-tumour immunity
Antagonist
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
Targeting MDM2, the antagonist of the tumor suppressor p53
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
The MDM2 gene family
Acid affairs in anti-tumour immunity
Antagonist